SUO 2020: Debate: Relugolix for Advanced Prostate Cancer is the New Standard (The HERO Study)
(UroToday.com) During the second prostate cancer session at the 2020 Annual Meeting of the Society of Urologic Oncology (SUO), Drs. Neal Shore and Ashley Evan Ross debated the use of relugolix as a new standard of care for androgen deprivation therapy (ADT) for the treatment of prostate cancer.
This debate follows the publication of the HERO trial,
1
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO), which was published in the New England Journal of Medicine in June 2020 and of which Dr. Shore is the lead author. This was a randomized controlled comparing relugolix, an oral gonadotropin-releasing hormone antagonist, to leuprolide. 120mg relugolix was given by mouth daily and leuprolide was given every 3 months as depot injections. The primary end point was “sustained castration”, meaning a testosterone level
SUO 2020: Optimizing Management of High Risk Non-Muscle-Invasive Bladder Cancer – Case Based Discussion
(UroToday.com) The plenary session of the last day of the 2020 Annual Meeting of the Society of Urologic Oncology (SUO) began with a panel discussion stepping through the case of a patient with non-muscle invasive bladder cancer.
Dr. Sima Porten, the moderator, introduced the case: a 60-year-old otherwise healthy male with high-volume high-grade Ta urothelial carcinoma of the bladder diagnosed on an initial transurethral resection (TUR) with no muscle in the initial specimen.
The panel first addressed the question of perioperative chemotherapy for this patient. There was immediate resounding consensus that, based on the results of SWOG S0337